Press Room

bonus 1a

Press Releases 2023

Amidst the Gaza War, Deployment of Limb-Saving Treatment Expands to Southern Israel as Part of a Clinical Trial Bonus Biogroup is pleased to announce the enrollment of Barzilai Ashkelon University Medical Center ("Barzilai Hospital") in a clinical trial for treating limb bone defects using BonoFill - a living human bone…
Bonus Biogroup Recognized Among Top Four Companies in Cell Therapy Biotech Innovation at Advanced Therapies Week 2024 in Miami, Florida Bonus Biogroup is proud to announce its selection as one of the top four global leaders in cell therapy innovation, a remarkable distinction among hundreds of biotechnology companies [1]. This…
Results Presented at the International Conference – Advanced Therapies Europe 2023 Bonus Biogroup is pleased to announce the successful demonstration of MesenCure's effectiveness in treating osteoarthritis in preclinical trials (hereafter: "the trial for osteoarthritis treatment") [1]. This achievement follows a clinical trial that underscored MesenCure's success in mitigating inflammation and…
World's First Successful Joint Fusion with BonoFill™: A Lab-Grown Human Bone Graft by Bonus Biogroup Eliminates Self-Bone Transplantation in Phase II Clinical Trial for Limb Bone Defects. Success Reported in a Keynote Presentation at the World Orthopedics Conference 2023. Bonus Biogroup proudly announces a global first: the successful fusion of…
Bonus Biogroup Showcased Breakthrough Trial Results at International Drug Development Seminar at the invitation of Jackson Laboratory, USA. Bonus Biogroup is delighted to announce the successful preclinical demonstration [1] of MesenCure's effectiveness in treating lethal toxicity induced by chemotherapy drugs, such as Cisplatin and Bleomycin, routinely used in cancer treatment.…
Company Showcased Bone Regeneration Success at ICOMS 2023, Following Invitation from the International Association for Oral and Maxillofacial Surgery. Bonus Biogroup is pleased to announce the compelling findings after the six-month follow-up period for twenty out of thirty transplants of BonoFill, our living human bone graft, in Phase II Clinical…
Bonus Biogroup's Bioinformatics Unit presents its first achievements at the Paris 2023 annual meeting of the International Society for Cell and Gene Therapy (ISCT), highlighting accomplishments across various R&D programs. Bonus BioGroup (TASE: BONS), a clinical-stage Israeli biotechnology company engaged in research and development of biomedical tissue-engineered and cell therapy…
Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce entering an advanced stage in a joint trial in partnership with the Israel Institute for Biological Research (the "IIBR"). This study explores,…
The drug MesenCure reduced life-threatening cytokine release syndrome, which occurred as a result of immunotherapy for the treatment of cancer Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce that Jackson…
Collaboration with one of Europe's leading research centers in personalized medicine aims to accelerate clinical development. Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is delighted to announce the signing of a strategic cooperation…
Orthopedic Surgeons to Showcase Successful Treatment of Bone Deficiencies with BonoFill, a Live Human Bone Graft by Bonus Biogroup Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce that orthopedic surgeons…
The Israel Ministry of Health certified the facility and process for producing the investigational drug MesenCure to comply with Good Manufacturing Practices (GMP) according to the recommendations of the World Health Organization. Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered…

INFORMATION FOR INVESTORS  |  CAREER OPPORTUNITIES  |  INFORMATION FOR PATIENTS   |   RESEARCH COLLABORATIONS & BUSINESS DEVELOPMENT INQUIRIES

INFORMATION FOR INVESTORS

CAREER OPPORTUNITIES

INFORMATION FOR PATIENTS

RESEARCH COLLABORATIONS & BUSINESS DEVELOPMENT INQUIRIES

MAIL ICON  info@bonus-bio.com

MAIL ICON  +972 (0)73 206 7104

MAIL ICONMatam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel

you tube linkedin facebook twitter

© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd

Please publish modules in offcanvas position.